Portfolio returned 41.1%, beating benchmark by 12.9 points

Both figures sit well outside Annolyse's historical baseline (portfolio mean 0.7%; benchmark mean 1.6%). NTA per share reached $1.77, an unprecedented high against the historical mean of $1.38 across the recent four-period window. Net assets attributable to shareholders rose to NZ$551.4m from NZ$345.4m (+59.7%), reflecting gains on investments of NZ$150.5m disclosed in the commentary alongside warrant exercises during the year. Reported NPAT of NZ$142.7m compared with NZ$1.7m in the COVID-affected FY20 base; the year-on-year growth percentage is dominated by mark-to-market movement and is not surfaced as a clean growth figure. The full-year dividend declared was 13.48 cps (FY20: 12.63 cps), with a 3.6 cps final component.

• A 12.9pp lead over the index is large in absolute terms and unprecedented in the supplied historical baseline. The commentary attributes the result to "the recovery of key portfolio stocks", which means investors should test how much of the spread came from concentrated recovery positions versus repeatable security selection in a market-wide rebound.

• NTA at $1.77 reflects portfolio revaluation, not income generation. Net assets grew NZ$206m, but investment income excluding fair-value movements fell to NZ$5.5m from NZ$6.1m (-10.9%). This matters because distribution coverage from underlying yield was only 25.4% (FY20: 33.1%) on the company's disclosed basis.

• Distributions are funded from capital returns, not recurring income. The company paid NZ$21.5m in distributions against NZ$5.5m of recurring investment income. That is sustainable while portfolio returns stay positive but introduces structural sensitivity to drawdowns. ROE of 25.9% (FY20: 0.5%) sits well above the historical mean of 0.4%, but that baseline includes loss-making periods and is dominated by mark-to-market movement in this year.

Against Annolyse's historical baseline, both portfolio total return and the benchmark return are unprecedented, so the reference point for next year is mean-reversion rather than a managed target. The HY21 share of full-year NPAT was 60.9% and of full-year investment income 61.3%, indicating a front-loaded recovery half within FY21. Because the FY20 base captured the March COVID drawdown, the half-shape is a function of timing rather than operating cadence. Forward dividend rate and any change to distribution policy following the higher net-asset base remain to be tested in subsequent periods.

Gains on investments of NZ$150.5m dominate the NZ$156.0m total income line, while recurring investment income (dividend plus interest) fell 10.9% to NZ$5.5m. ROE of 25.9% and the lift in net assets to NZ$551.4m therefore reflect mark-to-market revaluation across the equity book rather than realised yield.

For this reporting shape, the relevant durability test is the 12.9pp spread over benchmark and the persistence of NTA gains, not cash conversion or working-capital movement. Net cash outflow from operating activities of NZ$48.3m (FY20: NZ$33.8m outflow) reflects net portfolio purchases and capital deployment rather than an earnings-quality signal. Distribution coverage from recurring income narrowed to 25.4% on the disclosed basis, which means a sustained portfolio drawdown would force distributions to be funded from realised gains or capital. That is consistent with an NTA-plus-distribution return policy but is a structural feature investors should price explicitly.

This briefing cannot assess portfolio concentration, individual security weightings, or any forward management views not included in the supplied release commentary.